The aim of the present study was to explore how dynamic contrastenhanced magnetic resonance imaging (DCEMRI) may differentiate hepatocellular carcinoma (HCC) from hepatic metastasis of rectal cancer (HMRC) by extracting pharmacokinetic parameters and radiomic features. A total of 75 patients,
including 41 cases with HCC and 34 cases with HMRC, underwent DCEMRI examination. Dualinput twocompartment extended Tofts tracer kinetic model attached to a specialized image postprocessing software package from OmniKinetics; GE Healthcare was used to calculate the values of the
pharmacokinetic parameters and radiomic features, which were extracted from the lesions at the same region of interest. These values were evaluated using Student's ttest and receiver operating characteristic curves, and discriminant models were built to differentiate between HCC and HRMC.
The results identified statistically significant differences in the values of the pharmacokinetic parameters hepatic perfusion index (HPI), endothelial transfer constant (Ktrans), initial area under the gadolinium concentration curve during the first 60 sec (IAUC) between the HCC and
HRMC groups. In addition, statistically significant differences in 17 radiomic features were observed between the two groups (P<0.05). The areas under the receiver operating characteristic (ROC) curves of the pharmacokinetic parameters Ktrans, IAUC and HPI were 0.73, 0.77 and 0.67, respectively.
The range of the areas under the ROC curves of the 17 radiomic features with statistical differences was 0.630.79. In addition, when pharmacokinetic parameters and radiomic features were incorporated, the area under the ROC curve was 0.86. The accuracy of Fisher's discriminant analysis model
based on radiomic features was 89.3%, and the leaveoneout crossvalidation accuracy was 80.0%. In conclusion, DCEMRI was demonstrated to be useful in the differential diagnosis of HCC and HMRC by extracting pharmacokinetic parameters and radiomic features, and incorporation of the two paths
improved the diagnostic efficacy. A discriminant model based on radiomic features further enhanced the identification of HCC and HMRC.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Radiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China
GE Healthcare, Shanghai 200000, P.R. China
October 1, 2020
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites